Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
137.73
+0.50 (0.36%)
Oct 15, 2025, 4:00 PM EDT - Market closed
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 17 analysts that cover Neurocrine Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $164.94, which forecasts a 19.76% increase in the stock price over the next year. The lowest target is $115 and the highest is $195.
Price Target: $164.94 (+19.76%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 10 | 10 | 9 | 9 |
| Buy | 11 | 11 | 9 | 9 | 6 | 6 |
| Hold | 2 | 2 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 22 | 22 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $188 → $195 | Strong Buy | Maintains | $188 → $195 | +41.58% | Oct 9, 2025 |
| Needham | Needham | Strong Buy Maintains $161 → $170 | Strong Buy | Maintains | $161 → $170 | +23.43% | Sep 22, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $144 → $149 | Buy | Maintains | $144 → $149 | +8.18% | Sep 5, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $158 → $163 | Buy | Maintains | $158 → $163 | +18.35% | Sep 5, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $165 → $175 | Strong Buy | Maintains | $165 → $175 | +27.06% | Aug 1, 2025 |
Financial Forecast
Revenue This Year
2.85B
from 2.36B
Increased by 20.79%
Revenue Next Year
3.26B
from 2.85B
Increased by 14.73%
EPS This Year
4.53
from 3.29
Increased by 37.76%
EPS Next Year
6.62
from 4.53
Increased by 46.00%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0B | 3.6B | |||
| Avg | 2.8B | 3.3B | |||
| Low | 2.7B | 2.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.1% | 25.7% | |||
| Avg | 20.8% | 14.7% | |||
| Low | 12.9% | -3.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.58 | 8.94 | |||
| Avg | 4.53 | 6.62 | |||
| Low | 3.51 | 4.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 69.5% | 97.1% | |||
| Avg | 37.8% | 46.0% | |||
| Low | 6.6% | -10.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.